What is the long-term trend for Cumberland Pharmaceuticals's repayments of notes payable?

Over 3 years (2021 to 2024), Cumberland Pharmaceuticals's repayments of notes payable has grown at a -15.2% compound annual growth rate (CAGR), from $59M to $36M.

Cumberland Pharmaceuticals CPIX Repayments Of Notes Payable

Repayments Of Notes Payable at other companies

American Assets TrustAAT

$0-100%

CTO

Citius Oncology, Inc.CTOR

$20M-60.0%

Century CommunitiesCCS

$9M+15.6%

RGC ResourcesRGCO

$711.5K-84.3%

Ondas, Inc. ONDS

$305K+4,107%

Ivanhoe ElectricIE

$9.82M+134%

Other financials

Income statement

See full

Revenue$9.1M-22.0%

Gross profit$7.2M-30.0%

Operating income-$3.1M-342%

Net income-$3.3M-362%

EPS (diluted)-$0.22-375%

Balance sheet

See full

Cash & equivalents$11.0M-27.1%

Total debt$4.8M-7.1%

Total equity$21.6M-24.5%

Total assets$71.0M+1.5%

Cash flow

See full

Operating cash flow$387.0K-90.1%

CapEx--100%

Free cash flow$387.0K-89.9%

Valuation

See full

Market cap$97.09M+142%

Enterprise value$90.91M+212%

P/S2.3×+1.4×

Profitability

See full

Gross margin82.9%-1.4pp

Operating margin-17.2%-125pp

Net margin-17.6%-103pp

FCF margin3.3%—

Returns & leverage

See full

Return on equity-29.4%-86.3pp

Debt / equity0.2×0.0×

Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfNotesPayable.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's repayments of notes payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cumberland Pharmaceuticals's repayments of notes payable?: Cumberland Pharmaceuticals (CPIX) reported repayments of notes payable of $0 in Q1 2026.
How has Cumberland Pharmaceuticals's repayments of notes payable changed year-over-year?: Cumberland Pharmaceuticals's repayments of notes payable decreased by 100.0% year-over-year, from $10.04M to $0.
What is the long-term trend for Cumberland Pharmaceuticals's repayments of notes payable?: Over 3 years (2021 to 2024), Cumberland Pharmaceuticals's repayments of notes payable has grown at a -15.2% compound annual growth rate (CAGR), from $59M to $36M.